Suppr超能文献

变应原免疫疗法

Allergen immunotherapy.

作者信息

Boursiquot Jean-Nicolas, Gagnon Rémi, Quirt Jaclyn, Ellis Anne K

机构信息

Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Québec, Canada.

Division of Clinical Immunology & Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada.

出版信息

Allergy Asthma Clin Immunol. 2024 Dec 16;20(Suppl 3):66. doi: 10.1186/s13223-024-00935-2.

Abstract

Allergen immunotherapy (AIT) is a potentially disease-modifying therapy that is effective for the treatment of allergic rhinitis/conjunctivitis, allergic asthma and stinging insect hypersensitivity. The decision to proceed with AIT should be made on a case-by-case basis, based on a comprehensive evaluation of the patient, allergy testing and a thorough discussion with the patient about treatment goals, risks vs. benefits, and long-term commitment to the treatment plan. For those with allergic rhinitis and/or asthma, it is also important to consider individual patient factors, such as the degree to which symptoms can be reduced by avoidance measures and pharmacological therapy, the amount and type of medication required to control symptoms, the adverse effects of pharmacological treatment, and patient preferences.Since AIT is associated with a risk of anaphylaxis, it should only be prescribed by physicians who are adequately trained in the treatment of allergic conditions. Furthermore, for subcutaneous therapy, injections must be given under medical supervision in clinics that are equipped to manage anaphylaxis. In this article, we review the indications and contraindications, patient selection criteria, and details regarding the administration, safety and efficacy of AIT for allergens other than foods. Immunotherapy for food allergy will be discussed in the Oral Immunotherapy article in this supplement.

摘要

变应原免疫疗法(AIT)是一种具有潜在疾病改善作用的疗法,对治疗变应性鼻炎/结膜炎、变应性哮喘和昆虫叮咬过敏有效。是否进行AIT应根据具体情况,在对患者进行全面评估、过敏检测以及与患者就治疗目标、风险与获益以及对治疗方案的长期依从性进行深入讨论的基础上做出决定。对于患有变应性鼻炎和/或哮喘的患者,还应考虑个体患者因素,如通过避免措施和药物治疗可减轻症状的程度、控制症状所需药物的数量和类型、药物治疗的不良反应以及患者的偏好。由于AIT与过敏反应风险相关,因此仅应由在过敏性疾病治疗方面接受过充分培训的医生开具处方。此外,对于皮下注射疗法,必须在具备管理过敏反应能力的诊所内,在医疗监督下进行注射。在本文中,我们将回顾除食物以外的变应原的AIT的适应证和禁忌证、患者选择标准以及关于给药、安全性和有效性的详细信息。本增刊的《口服免疫疗法》一文将讨论食物过敏的免疫疗法。

相似文献

1
Allergen immunotherapy.变应原免疫疗法
Allergy Asthma Clin Immunol. 2024 Dec 16;20(Suppl 3):66. doi: 10.1186/s13223-024-00935-2.
2
Allergen-specific immunotherapy.变应原特异性免疫疗法。
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):53. doi: 10.1186/s13223-018-0282-5. eCollection 2018.
3
Allergen-specific immunotherapy.过敏原特异性免疫疗法。
Allergy Asthma Clin Immunol. 2011 Nov 10;7 Suppl 1(Suppl 1):S5. doi: 10.1186/1710-1492-7-S1-S5.
4
Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).IgE介导的过敏性疾病中变应原特异性免疫治疗指南:德国变态反应学与临床免疫学会(DGAKI)、儿科变态反应与环境医学学会(GPA)、德国变态反应科医生医学协会(AeDA)、奥地利变态反应与免疫学会(ÖGAI)、瑞士变态反应与免疫学会(SGAI)、德国皮肤病学会(DDG)、德国耳鼻咽喉头颈外科学会(DGHNO-KHC)、德国儿科学与青少年医学学会(DGKJ)、儿科肺病学会(GPP)、德国呼吸学会(DGP)、德国耳鼻喉外科医生协会(BV-HNO)、儿科医生与青年医生专业联合会(BVKJ)、肺科医生联邦协会(BDP)以及德国皮肤科医生协会(BVDD)的S2k指南
Allergo J Int. 2014;23(8):282-319. doi: 10.1007/s40629-014-0032-2.
6
Clinical Practice Guideline: Immunotherapy for Inhalant Allergy.临床实践指南:变应原吸入性免疫疗法。
Otolaryngol Head Neck Surg. 2024 Mar;170 Suppl 1(Suppl 1):S1-S42. doi: 10.1002/ohn.648.
9
Does evidence support the use of cat allergen immunotherapy?有证据支持使用猫过敏原免疫疗法吗?
Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):350-355. doi: 10.1097/ACI.0000000000000457.

引用本文的文献

2
Food oral immunotherapy.食物口服免疫疗法
Allergy Asthma Clin Immunol. 2025 Feb 12;20(Suppl 3):82. doi: 10.1186/s13223-025-00948-5.
3
Asthma.哮喘
Allergy Asthma Clin Immunol. 2025 Feb 10;20(Suppl 3):81. doi: 10.1186/s13223-025-00949-4.

本文引用的文献

1
Focused allergic rhinitis practice parameter for Canada.加拿大变应性鼻炎针对性诊疗规范
Allergy Asthma Clin Immunol. 2024 Aug 8;20(1):45. doi: 10.1186/s13223-024-00899-3.
2
Anaphylaxis: A 2023 practice parameter update.过敏反应:2023 年实践参数更新。
Ann Allergy Asthma Immunol. 2024 Feb;132(2):124-176. doi: 10.1016/j.anai.2023.09.015. Epub 2023 Dec 18.
3
Updates and Recent Advances on Venom Immunotherapy.毒液免疫疗法的更新与最新进展
Curr Treat Options Allergy. 2023 Apr 29:1-19. doi: 10.1007/s40521-023-00336-7.
4
Allergen immunotherapy: past, present and future.变应原免疫治疗:过去、现在和未来。
Nat Rev Immunol. 2023 May;23(5):317-328. doi: 10.1038/s41577-022-00786-1. Epub 2022 Oct 17.
10
EAACI Allergen Immunotherapy User's Guide.EAACI 过敏原免疫治疗用户指南。
Pediatr Allergy Immunol. 2020 May;31 Suppl 25(Suppl 25):1-101. doi: 10.1111/pai.13189.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验